Calcagno, A
Cusato, J
Marinaro, L
Trentini, L
Alcantarini, C
Mussa, M
Simiele, M
D'Avolio, A
Di Perri, G
Bonora, S
Article History
Received: 21 June 2015
Revised: 12 August 2015
Accepted: 19 August 2015
First Online: 6 October 2015
Competing interests
: AC has received grants, travel grants and speaker’s honoraria from Abbvie, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Gilead Sciences, Viiv and Janssen-Cilag. SB has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, Gilead Sciences, GlaxoSmithKline (GSK), MSD, Pfizer and Janssen-Cilag. GDP has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Ingelheim, BMS, Gilead Sciences, GSK, MSD, Pfizer, Roche and Tibotec (Johnson & Johnson). The remaining authors declare no conflict of interest.